Gilde Healthcare — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

GammaTilegammatile.com in 𝕏Mar 2023 · $45M

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells.

BiotechHealthtechMedical Devices

David G. Brachman, MD, FASTRO(Co-Founder and Chief Technology Officer)Heyoung McBride, MD, MS, FASTRO(Co-Founder)Peter Nakaji, MD(Co-Founder)inEmad Youssef, MD(Co-Founder)Theresa Thomas, MS, CCRC(Co-Founder)Per Langoe(Chief Executive Officer)in

Co-investorsAccelmed Partners BlueStone Venture Partners Evidity Health Capital FemHealth Ventures MedTech Venture Partners MVM Life Science Partners +1 more

Tagworks Pharmaceuticalstagworkspharma.com in 𝕏Jun 2023

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.

BiotechHealthtechMedical DevicesNijmegen, NL

Co-investorsBif Lightstone Ventures New Enterprise Associates (NEA)Novartis Venture Fund Ysios Capital Clarus Ventures +1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.